IN8BIO, Inc.
INAB- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001740279
No open-market purchases or sales by IN8BIO, Inc. insiders were filed in the last 90 days; 21 institutions reported holding it in 13F filings for Q2 2026, worth $5.35M in total; no superinvestor holds it.
Q4 2022 vs. Q3 2022
How the institutions holding IN8BIO, Inc. changed between Q3 2022 and Q4 2022.
All holders in Q4 2022All holders in Q3 2022
| Measure | Q3 2022 | Q4 2022 | Change |
|---|---|---|---|
| Holders | 17 | 16 | −1 |
| Shares | 1.20M | 1.21M | +7.30K (+0.6%) |
| Value | $2.42M | $2.79M | +$368.1K (+15.2%) |
New holders (4)
Institutions that held IN8BIO, Inc. at the end of Q4 2022 but not at the end of Q3 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Rock Creek Group, LP | 81,568 | $188.4K | 0.02% |
| Northern Trust Corp | 13,253 | $30.6K | 0.00% |
| Dimensional Fund Advisors LP | 11,153 | $26.0K | 0.00% |
| Bank of America Corp | 20 | $46 | 0.00% |
Sold out (5)
Institutions that held IN8BIO, Inc. at the end of Q3 2022 and filed for Q4 2022 without it.
| Institution | Shares, Q3 2022 | Value, Q3 2022 |
|---|---|---|
| Precept Management LLC | 50,000 | $101.0K |
| Warberg Asset Management LLC | 15,000 | $30.0K |
| United Asset Strategies, Inc. | 14,000 | $28.0K |
| Morgan Stanley | 1,513 | $3.00K |
| Royal Bank of Canada | 140 | $0 |